Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DURAGESIC-50 vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fentanyl is a potent synthetic opioid agonist primarily at μ-opioid receptors, with additional weak affinity for κ- and δ-opioid receptors. It increases potassium conductance and decreases calcium influx, leading to hyperpolarization and reduced neurotransmitter release, resulting in analgesia and sedation.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Management of persistent, moderate to severe chronic pain in opioid-tolerant patients requiring around-the-clock analgesia.
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
Apply one 50 mcg/h transdermal system every 72 hours; initiate at 25 mcg/h in opioid-naive patients; titrate based on response and tolerability.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Mean terminal elimination half-life 20–27 h (range 13–40 h). Prolonged with hepatic impairment, elderly, or obesity. Clinical context: Requires ~5 days to reach steady state; accumulation risk with continuous use.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Primarily metabolized by CYP3A4 to norfentanyl and other inactive metabolites. Minimal metabolism via CYP3A5. Less than 1% excreted unchanged in urine.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Primarily renal: ~75% as metabolites (mostly norfentanyl, <10% unchanged fentanyl); ~9% biliary/fecal; <10% excreted in urine as unchanged drug.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
~80–85% bound to serum proteins, primarily albumin and alpha-1-acid glycoprotein (AAG).
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
3–8 L/kg (mean ~4 L/kg). High Vd indicates extensive tissue distribution (e.g., muscle, fat). Clinical meaning: large reservoir; slow redistribution contributes to long half-life.
4-6 L/kg; large Vd indicates extensive tissue distribution
Transdermal: ~92% relative to IV fentanyl (due to first-pass metabolism avoidance; absolute bioavailability ~45% for gel reservoir, ~40% for matrix patch). Not used orally (poor bioavailability <30%).
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
GFR 30-59 m L/min: reduce dose by 50% and monitor closely. GFR <30 m L/min: contraindicated due to accumulation of active metabolite.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
Child-Pugh Class A: no adjustment needed. Child-Pugh Class B: reduce dose by 50% and monitor. Child-Pugh Class C: avoid use.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Approved for opioid-tolerant children ≥2 years; dose based on morphine equivalent daily dose (MEDD) conversion; apply system every 72 hours; initial dose not to exceed 25 mcg/h.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Start at lowest available dose (25 mcg/h) and titrate slowly; monitor for respiratory depression, sedation, and constipation; consider reduced clearance and increased sensitivity.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
WARNING: RISK OF MEDICATION ERRORS, ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL EXPOSURE; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P450 3A4 INTERACTION; RISK FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; and RISK OF SERIOUS, LIFE-THREATENING, OR FATAL RESPIRATORY DEPRESSION IN CHILDREN.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Risk of respiratory depression, especially in non-opioid-tolerant patients or with dose initiation/titration,Risk of hypotension, bradycardia, and QT prolongation,Risk of serotonin syndrome with serotonergic drugs,Risk of adrenal insufficiency with prolonged use,Risk of severe hypotension in patients with compromised ability to maintain blood pressure,Use caution in patients with head injury, increased intracranial pressure, or impaired consciousness,May obscure the course of acute abdominal conditions,Risk of withdrawal with abrupt discontinuation,Application site reactions,Fever may increase fentanyl absorption through the skin,Not indicated for acute or postoperative pain,Should be used only in opioid-tolerant patients for chronic pain
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Hypersensitivity to fentanyl or any component of the system,Opioid-non-tolerant patients (including patients with acute or postoperative pain),Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment,Suspected or known paralytic ileus,Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Avoid grapefruit and grapefruit juice as they may increase fentanyl levels. No other significant food interactions.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
FDA Pregnancy Category C. First trimester: No adequate human data; animal studies show increased risk of skeletal variations. Second and third trimesters: Prolonged use may cause neonatal opioid withdrawal syndrome and respiratory depression at birth. Avoid during labor due to risk of neonatal respiratory depression.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Fentanyl is excreted in breast milk. Milk-to-plasma ratio is approximately 0.87-1.0. Use caution; monitor infant for drowsiness, feeding difficulties, and respiratory depression. American Academy of Pediatrics recommends use only if benefit outweighs risk.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
Pregnancy can increase fentanyl clearance due to increased plasma volume and hepatic metabolism. Gradual dose increments may be needed to maintain analgesia. However, avoid use during labor and delivery. If required, use lowest effective dose and have resuscitation equipment available.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
Convert oral morphine to transdermal fentanyl using a 100:1 ratio (e.g., oral morphine 100 mg/day = fentanyl 100 mcg/hr patch). Rotate patch sites every 72 hours to avoid skin irritation; apply to non-irradiated, intact skin. Do not cut or damage the patch. Initiate only in opioid-tolerant patients. Titrate no more frequently than every 72 hours. Monitor for respiratory depression, especially in opioid-naive patients, COPD, or sleep apnea. Naloxone may be needed but duration of fentanyl action may exceed naloxone's effect. Heat exposure (e.g., fever, heating pads) increases absorption and risk of toxicity. Remove old patch before applying new one.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Apply patch to flat, non-hairy skin on chest, back, or upper arm; avoid irritated or scarred skin.,Wash hands after applying; do not touch the gel or cut the patch.,Dispose of used patches by folding adhesive sides together and flushing down toilet or placing in child-resistant container.,Avoid heating pads, hot tubs, electric blankets, or sunbathing while wearing patch.,Do not stop or change dose without talking to doctor; withdrawal may occur.,Keep patches out of reach of children and pets; accidental exposure can be fatal.,Common side effects include nausea, constipation, drowsiness, and dizziness.,Seek emergency care if you have trouble breathing, slow heartbeat, or severe drowsiness.,Do not drink alcohol or take other sedatives without doctor approval.,If patch falls off, apply a new one at a different site and note the time to track 72-hour schedule.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DURAGESIC-50 vs ABSTRAL, answered by our medical review team.
DURAGESIC-50 is a Opioid Analgesic that works by Fentanyl is a potent synthetic opioid agonist primarily at μ-opioid receptors, with additional weak affinity for κ- and δ-opioid receptors. It increases potassium conductance and decreases calcium influx, leading to hyperpolarization and reduced neurotransmitter release, resulting in analgesia and sedation.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DURAGESIC-50 and ABSTRAL depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DURAGESIC-50 is: Apply one 50 mcg/h transdermal system every 72 hours; initiate at 25 mcg/h in opioid-naive patients; titrate based on response and tolerability.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DURAGESIC-50 and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DURAGESIC-50 is classified as Category C. FDA Pregnancy Category C. First trimester: No adequate human data; animal studies show increased risk of skeletal variations. Second and third trimesters: Prolonged use may cause n. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.